{
    "CONTRACT_ID": "PW-22-01012574",
    "type": "ACAN",
    "department": "Department of National Defence",
    "procurement_category": "Goods and Services",
    "short_summary": "Purchase of 20ml vials of HI-6 DMS drug product with a concentration of 100mg/mL after reconstitution with 10ml of diluent or water for injection.",
    "description": "Advance Contract Award Notice (ACAN) for the manufacture and supply of HI-6 DMS drug product as a sterile lyophilized powder for solution to provide treatment from suspected exposure to chemical nerve agents.",
    "estimated_value": 5,
    "date_posted": "2022-11-04",
    "duration_in_months": ": 11 months + 1 year option period 5 times",
    "provinces": [
        "Ontario"
    ],
    "tags": [
        "Government of Canada",
        "Medical Research and Development - DND",
        "Health Services - Quebec",
        "Government Procurement-of Goods and Services",
        "Science Technology and Information Science Technology",
        "Technology",
        "Public Health Services",
        "Debts to pay",
        "Treatment and Services and-Lease"
    ],
    "full_summary": "### Tender Announcement\n\n#### Title\nManufacture and Supply of HI-6 Dimethanesulfonate (DMS) Lyophilized Powder for Solution\n\n#### Notification Reference\nPW-22-01012574\n\n#### Amendment Reference\n0\n\n#### Solicitation Number\nW6369-23-A008\n\n#### Publication Date\n04 November 2022\n\n#### Tender Closing Date and Time\n18 November 2022 at 14:00:00\n\n#### Goods or Services\nThe Department of National Defence (DND) is seeking a supplier for the manufacture and supply of HI-6 DMS drug product as a sterile lyophilized powder for solution.\n\n#### Specifications\n- The required product is a sterile lyophilized powder for solution in 20mL vials with a concentration of 100mg/mL after reconstitution with 10mL of diluent or water for injection.\n- The proposed manufacturing premises must contain suitable/sufficient equipment and personnel for the formulation, and fill, finish, and quality control of HI-6 dimethanesuflonate (DMS) lyophilized powder for solution drug product.\n\n#### Evaluation Criteria\nSubpliers are expected to meet the following requirements:\n- Minimum one-year experience with the formulation, fill, finish, and quality control of at least one batch of HI-6 dimethanesulfonate (DMS) lyophilized powder for solution drug product within the last 15 years as of the closing date.\n- Implemented a pharmaceutical quality system that incorporates Good Manufacturing Practices (GMP) and quality risk management of sufficient quality to comply with Part C, Division 2 of the Canadian Food and Drug Regulations.\n- Minimum two years of experience with the production of a small molecule sterile drug product of sufficient quality for a Phase I clinical trial within the last ten years as of the closing date.\n- The Bidder's person in charge of the Quality Control department must have educational qualifications and professional certifications/designations.\n\n#### Notice Type\nAdvance Contract Award Notice (ACAN)\n\n#### Trade Agreements\n- This tender is subject to the Canada-United Kingdom Trade Continuity Agreement, the Canada-European Union Comprehensive Economic and Trade Agreement, and other relevant trade agreements.\n\n#### Justification for Pre-Identified Supplier\nKABS Laboratories Inc. is the pre-identified supplier due to its previous qualification and validation of the manufacturing process for HI-6 DMS vials.\n\n#### Contact Information\nName: Natalie Provost\nTitle: Procurement and Contracting Officer\nEmail: Natalie.Provost"
}